FDA Approves Cue Health’s Point-of-Care COVID-19 Test Using Nasal Swabs

What You Should Know:

The Food and Drug Administration (FDA) has awarded Cue Health Emergency Use Authorization (EUA) for its rapid, portable, molecular point of care COVID-19 test.

The company recently raised $100M in Series C funding from Menlo Park-based Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation – JJDC, Inc., ACME Capital, and other investment firms.

Cue Health Inc. (“Cue”), a healthcare technology company, announced today that it has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the company’s rapid, portable, point-of-care COVID-19 test. The Cue COVID-19 Test

Leave a Reply